Tafluprost 0.0015% Eye Drops

How it works

Tafluprost selectively stimulates prostaglandin F2-alpha receptors, lowering intraocular pressure predominantly by enhancing uveoscleral aqueous outflow.

Prescribing in practice

• Patients should be warned about gradual and potentially permanent increased iris pigmentation, eyelid skin darkening and eyelash growth, which is more noticeable with unilateral treatment.
• Use with caution where there is risk of intraocular inflammation or macular oedema, such as aphakia or active uveitis.
• The preservative-free formulation is advantageous for patients with ocular surface disease or preservative sensitivity.

Monitoring

Monitor intraocular pressure to confirm efficacy and review periodically for pigmentary changes and ocular surface tolerance.

Counselling the patient

• Apply once daily, usually in the evening, and continue regularly despite the absence of symptoms.
• Changes to iris colour, eyelid skin and lashes can occur and may be permanent.
• Brief blurring after instillation is normal.

Evidence & guidelines

Prostaglandin analogues such as tafluprost are endorsed by NICE as a first-line treatment for raised intraocular pressure in open-angle glaucoma and ocular hypertension.